Once-daily lixisenatide in combination with basal insulin ± OADs in patients with type 2 diabetes selectively reduces postprandial hyperglycaemic daytime exposure

被引：0
|
作者：
Gomez-Huelgas, R. [1 ]
Riddle, M. C. [2 ]
Seino, Y. [3 ]
Cariou, B. [4 ]
Roy-Duval, C. [5 ]
Hecquet, C. [5 ]
DiGenio, A. [6 ]
Rosenstock, J. [7 ]
机构：
[1] Hosp Reg Univ Carlos Haya, Dept Internal Med, Malaga, Spain
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Kansai Elect Power Hosp, Osaka, Japan
[4] Nantes Univ Hosp, Dept Endocrinol, Paris, France
[5] Sanofi, Paris, France
[6] Sanofi, Bridgewater, MA USA
[7] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1005
引用
下载
收藏
页码：S403 / S403
页数：1
相关论文
共 50 条
  • [31] Study of Once-Daily Levemir (SOLVE™): Patient quality of life and physician resource utilisation of once-daily insulin detemir in Chinese patients with type 2 diabetes
    Pan, C.
    Lu, J.
    Wang, P.
    Ji, Q.
    Ji, L.
    DIABETOLOGIA, 2012, 55 : S389 - S390
  • [32] Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
    Kapitza, C.
    Forst, T.
    Coester, H. -V.
    Poitiers, F.
    Ruus, P.
    Hincelin-Mery, A.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07): : 642 - 649
  • [33] Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China
    Hu, Shanshan
    Wang, Shuowen
    Gu, Shengying
    Qi, Chendong
    Shi, Chenyang
    Fan, Guorong
    DIABETES OBESITY & METABOLISM, 2024,
  • [34] Efficacy of Adding Once-Daily Insulin Glulisine in Japanese Type 2 Diabetes Patients Treated with Insulin Glargine and Sitagliptin
    Takahara, Mitsuyoshi
    Shiraiwa, Toshihiko
    Katakami, Naoto
    Matsuoka, Taka-aki
    Shimomura, Iichiro
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (10) : 633 - 639
  • [35] Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan
    Seino, Yutaka
    Yabe, Daisuke
    Takami, Akane
    Niemoeller, Elisabeth
    Takagi, Hiroki
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1304 - 1309
  • [36] Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
    Riddle, Matthew C.
    Aronson, Ronnie
    Home, Philip
    Marre, Michel
    Niemoeller, Elisabeth
    Miossec, Patrick
    Ping, Lin
    Ye, Jenny
    Rosenstock, Julio
    DIABETES CARE, 2013, 36 (09) : 2489 - 2496
  • [37] Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study
    Kumar, S.
    Jang, H. C.
    Demirag, N. G.
    Skjoth, T. V.
    Endahl, L.
    Bode, B.
    DIABETIC MEDICINE, 2017, 34 (02) : 180 - 188
  • [38] WHEN IS ENOUGH, ENOUGH? THE CORRELATION BETWEEN ONCE-DAILY BASAL INSULIN DOSES TO THE FASTING PLASMA GLUCOSE IN TYPE 2 DIABETES
    King, Allen B.
    ENDOCRINE PRACTICE, 2013, 19 (04) : 735 - 736
  • [39] Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin
    Rosenstock, J.
    Diamant, M.
    Silvestre, L.
    Souhami, E.
    Zhou, T.
    Fonseca, V.
    DIABETOLOGIA, 2014, 57 : S108 - S108
  • [40] Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
    Bue-Valleskey, Juliana M.
    Kazda, Christof M.
    Ma, Chenchen
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Haupt, Axel
    Frias, Juan P.
    DIABETES CARE, 2023, 46 (05) : 1060 - 1067
12345